Vericel Corp
NASDAQ:VCEL

Watchlist Manager
Vericel Corp Logo
Vericel Corp
NASDAQ:VCEL
Watchlist
Price: 39.82 USD -0.28% Market Closed
Market Cap: 2B USD
Have any thoughts about
Vericel Corp?
Write Note
Section:
 

Relative Value

The Relative Value of one VCEL stock under the Base Case scenario is 39.36 USD. Compared to the current market price of 39.82 USD, Vericel Corp is Overvalued by 1%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VCEL Relative Value
Base Case
39.36 USD
Overvaluation 1%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

8.4
P/S
P/S
Price to Sales
8.4
vs History
73
vs Industry
44
Median 3Y
9.1
Median 5Y
9.5
Industry
7.5
Forward
6.9
More Details
671.9
P/E
P/E
Price to Earnings
671.9
vs History
30
vs Industry
0
Median 3Y
-70.4
Median 5Y
245.7
Industry
23.6
Forward
159.1
More Details
34.8
P/OCF
P/OCF
Price to OCF
34.8
vs History
95
vs Industry
4
Median 3Y
55.3
Median 5Y
59.9
Industry
20.2
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
0
Median 3Y
99.1
Median 5Y
99.1
Industry
22.9
More Details
6.8
P/B
P/B
Price to Book Value
6.8
vs History
85
vs Industry
11
Median 3Y
8
Median 5Y
8.4
Industry
2.8
More Details
7.9
EV/S
EV/S
Enterprise Value to Sales
7.9
vs History
69
vs Industry
37
Median 3Y
8.5
Median 5Y
8.9
Industry
7.7
Forward
6.5
More Details
10.9
EV/GP
EV/GP
Enterprise Value to Gross Profit
10.9
vs History
77
vs Industry
33
Median 3Y
12.5
Median 5Y
13.1
Industry
9.6
More Details
471.8
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
471.8
vs History
33
vs Industry
0
Median 3Y
-76.6
Median 5Y
242.4
Industry
4.9
Forward
25.1
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
0
Median 3Y
-113.9
Median 5Y
-106.1
Industry
4.9
Forward
157.6
More Details
32.8
EV/OCF
EV/OCF
Enterprise Value to OCF
32.8
vs History
95
vs Industry
4
Median 3Y
51.6
Median 5Y
56
Industry
5.4
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
0
Median 3Y
90.9
Median 5Y
95
Industry
4
More Details
6.4
EV/IC
EV/IC
Enterprise Value to IC
6.4
vs History
96
vs Industry
23
Median 3Y
8.4
Median 5Y
9.5
Industry
5.1
More Details

Multiples Across Competitors

VCEL Competitors Multiples
Vericel Corp Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vericel Corp
NASDAQ:VCEL
2B USD 8.4 671.9 471.8 -672.4
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 980 524.7 -161 504.4 -196 117.9 -193 879.9
US
Abbvie Inc
NYSE:ABBV
338.3B USD 5.9 81.4 15.5 22.9
US
Amgen Inc
NASDAQ:AMGN
159.7B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
139.6B USD 4.9 23.4 10.2 14
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.4B USD 10.9 -122.7 26.1 27.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 073.2 -529 -576.1 -560.7
AU
CSL Ltd
ASX:CSL
120.8B AUD 5.2 28.8 17.7 22.1
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
61.7B USD 4.4 13.7 12.3 13.8
US
Seagen Inc
F:SGT
39.3B EUR 20 -61.2 -66 -59.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.1B USD 17.5 -152.6 -683.9 -342.7
P/S Multiple
Revenue Growth P/S to Growth
US
Vericel Corp
NASDAQ:VCEL
Average P/S: 3 089 334.5
8.4
24%
0.3
FR
Pharnext SCA
OTC:PNEXF
33 980 524.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.9
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.7
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.9
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.9
10%
1.1
US
E
Epizyme Inc
F:EPE
2 073.2
N/A N/A
AU
CSL Ltd
ASX:CSL
5.2
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.4
4%
1.1
US
S
Seagen Inc
F:SGT
20
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.5
30%
0.6
P/E Multiple
Earnings Growth PEG
US
Vericel Corp
NASDAQ:VCEL
Average P/E: 141
671.9
88%
7.6
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 504.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.4
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.4
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -122.7 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -529 N/A N/A
AU
CSL Ltd
ASX:CSL
28.8
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.7
7%
2
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -152.6 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Vericel Corp
NASDAQ:VCEL
Average EV/EBITDA: 81.1
471.8
143%
3.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 117.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.5
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.1
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -576.1 N/A N/A
AU
CSL Ltd
ASX:CSL
17.7
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.3
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -683.9 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Vericel Corp
NASDAQ:VCEL
Average EV/EBIT: 20.7
Negative Multiple: -672.4
166%
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 879.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.9
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.4
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -560.7 N/A N/A
AU
CSL Ltd
ASX:CSL
22.1
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.8
11%
1.3
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.6 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -342.7 N/A N/A

See Also

Summary
VCEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
VCEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
VCEL stock valuation using valuation multiples.
Wall Street Estimates
VCEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
VCEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 267,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.